Author (identification) | State or country | Year | Study design | Patient population | Date | Screening protocol | Screened (n) | Patients with BCVI (n) | Treatment | Outcomes measured |
Cothren et al22 | Denver | 2004 | Retrospective cohort | Blunt trauma | 1996–2002 | Denver | 643 | 114 CAI | Antithrombotic vs. no treatment | Stroke |
Snow et al13 | Australia | 2015 | Retrospective cohort | Blunt trauma | 2006–2011 | No | NA | 41 | Antithrombotic vs. no treatment | Stroke |
Biffl et al24 | Denver | 1999 | Retrospective cohort | Blunt trauma | 1990–1999 | Denver* | NA | 76 | Heparin vs. no heparin | Vessel healing |
Wei et al11 | Canada | 2010 | Retrospective cohort | Blunt trauma | 2006–2009 | Denver | 222 | 27 | Medical vs. endovascular vs. no treatment | Stroke |
Miller et al6 | Memphis | 2001 | Retrospective cohort | Blunt trauma | 1995–1999 | NA | NA | 96 | Heparin vs. aspirin vs. no treatment | Stroke |
Stein et al19 | Baltimore | 2009 | Retrospective cohort | Blunt trauma | 2003–2005 | NA | NA | 147 | Any treatment vs. no treatment | Stroke |
Cothren et al21 | Denver | 2005 | Prospective cohort | Grade III CAI | 1996–2005 | NA | NA | 140 | Stent vs. no stent | Stroke |
Malhotra et al20 | Virginia | 2007 | Prospective cohort | Blunt trauma | 2005–2007 | Yes† | 119 | 26 | Anticoagulation vs. antiplatelet vs. stent | Stroke |
Wagenaar et al10 | Denver | 2014 | Retrospective cohort | Blunt trauma | 1997–2013 | Denver | NA | 582 | Any treatment vs. no treatment | Stroke and vessel healing |
Callcut et al16 | Cincinnati | 2012 | Retrospective cohort | Blunt trauma with TBI | 1998–2008 | No | NA | 77 | Any treatment vs. no treatment | Stroke |
Burlew et al14 | Denver | 2014 | Retrospective cohort | Grade II/III BCVI | 1996–2011 | Denver | NA | 195 | Antithrombotic vs. stent | Stroke |
DiCocco et al17 | Memphis | 2011 | Retrospective cohort | Blunt trauma | 2005–2009 | Memphis | NA | 200 | Antithrombotic vs. stent | Stroke |
Miller et al23 | Memphis | 2002 | Prospective cohort | Blunt trauma | Unknown vs. 1995–1999 | Memphis | NA | 63 | Antithrombotic vs. no treatment | Stroke |
Biffl et al2 | Denver | 2000 | Retrospective cohort | Blunt trauma | 1996–1999 | Yes† | NA | 38 VAI | Heparin vs. no heparin | Stroke |
Cothren9 | Denver | 2009 | Retrospective cohort | Blunt trauma | 1997–2007 | Denver | NA | 282 | Heparin vs. aspirin vs. dual platelet vs. no treatment | Stroke |
Biffl et al7 | Denver | 2002 | Retrospective cohort | Blunt trauma | 1990–2001 | Yes† | NA | 171 | Heparin vs. aspirin | Stroke and vessel healing |
Lebl et al15 | Boston | 2013 | Retrospective cohort | Blunt trauma | 2007–2010 | No | 253 | 41 VAI | None vs. aspirin vs. heparin/coumadin | Stroke |
Hwang et al18 | Australia | 2010 | Retrospective cohort | Blunt trauma | 2003–2006 | No | NA | 67 | Anticoagulation vs. antiplatelet vs. stent | Stroke |
Catapano et al5 | Phoenix | 2020 | Retrospective cohort | Blunt trauma | 2010–2017 | Denver | NA | 94 | Medical vs. endovascular vs. no treatment | Stroke |
*Began in 1996.
†Institution-specific.
BCVI, blunt cerebrovascular injury; CAI, carotid artery injury; NA, not available; TBI, traumatic brain injury; VAI, vertebral artery injury.